The National Lung Cancer Audit: The Impact of COVID-19
Since 2014, the National Lung Cancer Audit (NLCA) has been evaluating the performance of the UK NHS lung cancer services against established standards of care. Prior to the onset of the COVID-19 pandemic, the NLCA's annual reports revealed a steady stream of improvements in early diagnosis, acc...
Gespeichert in:
| Veröffentlicht in: | Clinical oncology (Royal College of Radiologists (Great Britain)) 2022-11, Vol.34 (11), p.701-707 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 707 |
|---|---|
| container_issue | 11 |
| container_start_page | 701 |
| container_title | Clinical oncology (Royal College of Radiologists (Great Britain)) |
| container_volume | 34 |
| creator | Conibear, J. Nossiter, J. Foster, C. West, D. Cromwell, D. Navani, N. |
| description | Since 2014, the National Lung Cancer Audit (NLCA) has been evaluating the performance of the UK NHS lung cancer services against established standards of care. Prior to the onset of the COVID-19 pandemic, the NLCA's annual reports revealed a steady stream of improvements in early diagnosis, access to surgery, treatment with anti-cancer therapies, input from specialist nursing and survival for patients with lung cancer in the NHS. In January 2022, the NLCA reported on the negative impact COVID-19 has had on all aspects of the lung cancer diagnosis and treatment pathway within the NHS. This article details the fundamental changes made to the NLCA data collection and analysis process during the COVID-19 pandemic and details the negative impact COVID-19 had on NHS lung cancer patient outcomes during 2020. |
| doi_str_mv | 10.1016/j.clon.2022.09.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9474418</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0936655522004095</els_id><sourcerecordid>2720427970</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-5b7428885d0b71132c4be8936528642a949c2c90cf502177a5a561ff622ad6783</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EouXxAyxQlmwSbMePGCGkKrwqVbApbC3XccBVGhc7QeLvcdRSwYbVLObcO6MDwBmCGYKIXS4z3bg2wxDjDIoMQrwHxojkeYpFgfbBGIqcpYxSOgJHISxhJIpCHIJRzlABc8rGgM3fTfKkOuta1SSzvn1LStVq45NJX9nuKhn209Va6S5xdVI-v05vUyROwEGtmmBOt_MYvNzfzcvHdPb8MC0ns1QTSruULjiJJwtawQVHKMeaLEwRv6K4YAQrQYTGWkBdU4gR54oqylBdM4xVxXiRH4ObTe-6X6xMpU3bedXItbcr5b-kU1b-3bT2Xb65TykIJwQNBRfbAu8-ehM6ubJBm6ZRrXF9kJhjSDAXHEYUb1DtXQje1LszCMpBuFzKQbgchEsoZNQZQ-e_H9xFfgxH4HoDmKjp0xovg7YmGq6sN7qTlbP_9X8DbwqOgA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2720427970</pqid></control><display><type>article</type><title>The National Lung Cancer Audit: The Impact of COVID-19</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Conibear, J. ; Nossiter, J. ; Foster, C. ; West, D. ; Cromwell, D. ; Navani, N.</creator><creatorcontrib>Conibear, J. ; Nossiter, J. ; Foster, C. ; West, D. ; Cromwell, D. ; Navani, N.</creatorcontrib><description>Since 2014, the National Lung Cancer Audit (NLCA) has been evaluating the performance of the UK NHS lung cancer services against established standards of care. Prior to the onset of the COVID-19 pandemic, the NLCA's annual reports revealed a steady stream of improvements in early diagnosis, access to surgery, treatment with anti-cancer therapies, input from specialist nursing and survival for patients with lung cancer in the NHS. In January 2022, the NLCA reported on the negative impact COVID-19 has had on all aspects of the lung cancer diagnosis and treatment pathway within the NHS. This article details the fundamental changes made to the NLCA data collection and analysis process during the COVID-19 pandemic and details the negative impact COVID-19 had on NHS lung cancer patient outcomes during 2020.</description><identifier>ISSN: 0936-6555</identifier><identifier>ISSN: 1433-2981</identifier><identifier>EISSN: 1433-2981</identifier><identifier>DOI: 10.1016/j.clon.2022.09.002</identifier><identifier>PMID: 36180356</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Audit ; cancer ; COVID-19 ; COVID-19 - epidemiology ; Humans ; improvement ; Lung ; Lung Neoplasms - epidemiology ; Lung Neoplasms - therapy ; national ; NHS ; NLCA ; pandemic ; Pandemics ; surgery ; survival</subject><ispartof>Clinical oncology (Royal College of Radiologists (Great Britain)), 2022-11, Vol.34 (11), p.701-707</ispartof><rights>2022</rights><rights>Crown Copyright © 2022. Published by Elsevier Ltd. All rights reserved.</rights><rights>Crown Copyright © 2022 Published by Elsevier Ltd on behalf of The Royal College of Radiologists. All rights reserved. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-5b7428885d0b71132c4be8936528642a949c2c90cf502177a5a561ff622ad6783</citedby><cites>FETCH-LOGICAL-c455t-5b7428885d0b71132c4be8936528642a949c2c90cf502177a5a561ff622ad6783</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.clon.2022.09.002$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36180356$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Conibear, J.</creatorcontrib><creatorcontrib>Nossiter, J.</creatorcontrib><creatorcontrib>Foster, C.</creatorcontrib><creatorcontrib>West, D.</creatorcontrib><creatorcontrib>Cromwell, D.</creatorcontrib><creatorcontrib>Navani, N.</creatorcontrib><title>The National Lung Cancer Audit: The Impact of COVID-19</title><title>Clinical oncology (Royal College of Radiologists (Great Britain))</title><addtitle>Clin Oncol (R Coll Radiol)</addtitle><description>Since 2014, the National Lung Cancer Audit (NLCA) has been evaluating the performance of the UK NHS lung cancer services against established standards of care. Prior to the onset of the COVID-19 pandemic, the NLCA's annual reports revealed a steady stream of improvements in early diagnosis, access to surgery, treatment with anti-cancer therapies, input from specialist nursing and survival for patients with lung cancer in the NHS. In January 2022, the NLCA reported on the negative impact COVID-19 has had on all aspects of the lung cancer diagnosis and treatment pathway within the NHS. This article details the fundamental changes made to the NLCA data collection and analysis process during the COVID-19 pandemic and details the negative impact COVID-19 had on NHS lung cancer patient outcomes during 2020.</description><subject>Audit</subject><subject>cancer</subject><subject>COVID-19</subject><subject>COVID-19 - epidemiology</subject><subject>Humans</subject><subject>improvement</subject><subject>Lung</subject><subject>Lung Neoplasms - epidemiology</subject><subject>Lung Neoplasms - therapy</subject><subject>national</subject><subject>NHS</subject><subject>NLCA</subject><subject>pandemic</subject><subject>Pandemics</subject><subject>surgery</subject><subject>survival</subject><issn>0936-6555</issn><issn>1433-2981</issn><issn>1433-2981</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtOwzAQRS0EouXxAyxQlmwSbMePGCGkKrwqVbApbC3XccBVGhc7QeLvcdRSwYbVLObcO6MDwBmCGYKIXS4z3bg2wxDjDIoMQrwHxojkeYpFgfbBGIqcpYxSOgJHISxhJIpCHIJRzlABc8rGgM3fTfKkOuta1SSzvn1LStVq45NJX9nuKhn209Va6S5xdVI-v05vUyROwEGtmmBOt_MYvNzfzcvHdPb8MC0ns1QTSruULjiJJwtawQVHKMeaLEwRv6K4YAQrQYTGWkBdU4gR54oqylBdM4xVxXiRH4ObTe-6X6xMpU3bedXItbcr5b-kU1b-3bT2Xb65TykIJwQNBRfbAu8-ehM6ubJBm6ZRrXF9kJhjSDAXHEYUb1DtXQje1LszCMpBuFzKQbgchEsoZNQZQ-e_H9xFfgxH4HoDmKjp0xovg7YmGq6sN7qTlbP_9X8DbwqOgA</recordid><startdate>20221101</startdate><enddate>20221101</enddate><creator>Conibear, J.</creator><creator>Nossiter, J.</creator><creator>Foster, C.</creator><creator>West, D.</creator><creator>Cromwell, D.</creator><creator>Navani, N.</creator><general>Elsevier Ltd</general><general>Published by Elsevier Ltd on behalf of The Royal College of Radiologists</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20221101</creationdate><title>The National Lung Cancer Audit: The Impact of COVID-19</title><author>Conibear, J. ; Nossiter, J. ; Foster, C. ; West, D. ; Cromwell, D. ; Navani, N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-5b7428885d0b71132c4be8936528642a949c2c90cf502177a5a561ff622ad6783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Audit</topic><topic>cancer</topic><topic>COVID-19</topic><topic>COVID-19 - epidemiology</topic><topic>Humans</topic><topic>improvement</topic><topic>Lung</topic><topic>Lung Neoplasms - epidemiology</topic><topic>Lung Neoplasms - therapy</topic><topic>national</topic><topic>NHS</topic><topic>NLCA</topic><topic>pandemic</topic><topic>Pandemics</topic><topic>surgery</topic><topic>survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Conibear, J.</creatorcontrib><creatorcontrib>Nossiter, J.</creatorcontrib><creatorcontrib>Foster, C.</creatorcontrib><creatorcontrib>West, D.</creatorcontrib><creatorcontrib>Cromwell, D.</creatorcontrib><creatorcontrib>Navani, N.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical oncology (Royal College of Radiologists (Great Britain))</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Conibear, J.</au><au>Nossiter, J.</au><au>Foster, C.</au><au>West, D.</au><au>Cromwell, D.</au><au>Navani, N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The National Lung Cancer Audit: The Impact of COVID-19</atitle><jtitle>Clinical oncology (Royal College of Radiologists (Great Britain))</jtitle><addtitle>Clin Oncol (R Coll Radiol)</addtitle><date>2022-11-01</date><risdate>2022</risdate><volume>34</volume><issue>11</issue><spage>701</spage><epage>707</epage><pages>701-707</pages><issn>0936-6555</issn><issn>1433-2981</issn><eissn>1433-2981</eissn><abstract>Since 2014, the National Lung Cancer Audit (NLCA) has been evaluating the performance of the UK NHS lung cancer services against established standards of care. Prior to the onset of the COVID-19 pandemic, the NLCA's annual reports revealed a steady stream of improvements in early diagnosis, access to surgery, treatment with anti-cancer therapies, input from specialist nursing and survival for patients with lung cancer in the NHS. In January 2022, the NLCA reported on the negative impact COVID-19 has had on all aspects of the lung cancer diagnosis and treatment pathway within the NHS. This article details the fundamental changes made to the NLCA data collection and analysis process during the COVID-19 pandemic and details the negative impact COVID-19 had on NHS lung cancer patient outcomes during 2020.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>36180356</pmid><doi>10.1016/j.clon.2022.09.002</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0936-6555 |
| ispartof | Clinical oncology (Royal College of Radiologists (Great Britain)), 2022-11, Vol.34 (11), p.701-707 |
| issn | 0936-6555 1433-2981 1433-2981 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9474418 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Audit cancer COVID-19 COVID-19 - epidemiology Humans improvement Lung Lung Neoplasms - epidemiology Lung Neoplasms - therapy national NHS NLCA pandemic Pandemics surgery survival |
| title | The National Lung Cancer Audit: The Impact of COVID-19 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T06%3A34%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20National%20Lung%20Cancer%20Audit:%20The%20Impact%20of%20COVID-19&rft.jtitle=Clinical%20oncology%20(Royal%20College%20of%20Radiologists%20(Great%20Britain))&rft.au=Conibear,%20J.&rft.date=2022-11-01&rft.volume=34&rft.issue=11&rft.spage=701&rft.epage=707&rft.pages=701-707&rft.issn=0936-6555&rft.eissn=1433-2981&rft_id=info:doi/10.1016/j.clon.2022.09.002&rft_dat=%3Cproquest_pubme%3E2720427970%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2720427970&rft_id=info:pmid/36180356&rft_els_id=S0936655522004095&rfr_iscdi=true |